Intranasal Fentanyl Versus Fentanyl Pectin Nasal Spray for the Management of Breakthrough Cancer Pain in Doses Proportional to Basal Opioid Regimen.
Mercadante S1, Prestia G2, Adile C2, Casuccio A3.
J Pain. 2014 Feb 19.
Abstract
The
aim of this randomized, crossover, comparison study was to assess the
analgesic and adverse effects of 2 nasal preparations, intranasal
fentanyl (INFS) and fentanyl pectin nasal spray (FPNS), for breakthrough pain,
given in doses proportional to opioid basal regimen. Each patient
randomly received INFS or FPNS in doses proportional to opioid dosages
used for background analgesia for 2 pairs of episodes. For each episode
of breakthrough pain, pain
intensity and adverse effects intensity were recorded just before
starting the INFS or FPNS (T0) and 5 minutes (T5), 10 minutes (T10), and
20 minutes (T20) after the administration of the nasal drugs.
Sixty-nine patients were studied.
The mean age was 63.4 years, and 37
patients were males. For the present analysis, 188 episodes were
considered.
A statistical decrease in pain intensity was observed with both nasal drugs after 5, 10, and 20 minutes.
A decrease in pain
intensity of >33% was observed in 16, 102, and 159 treated episodes
at T5, T10, and T20, respectively.
Adverse effects were of mild nature
in most cases or were preexistent because of basal opioid therapy.
No
differences were found in summed pain
intensity difference 20 minutes after dosing.
Most of patients did not
find substantial preferences.
INFS and FPNS were effective and
well-tolerated treatments for breakthrough pain
management.
Both delivery systems, in doses proportional to the basal
opioid regimen, provided significant analgesia within 10 minutes,
without producing relevant adverse effects.
PERSPECTIVE:
This
article showed that INFS and FPNS in doses proportional to basal opioid
regimen are equally safe and effective for the management of breakthrough pain in cancer patients. The present data provide new insights on the use of nasal preparations of fentanyl.
No comments:
Post a Comment